GUANGZHOU-INFORMATION
18.11.2023 13:07:35 CET | Business Wire | Press release
China’s Guangzhou launched a special conversation on November 16 in Italy’s Rome, at which more than a dozen guests from both countries told their stories about cultural and economic cooperation, showcased the fruitful achievements between two sides.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231118396482/en/
China’s Guangzhou launches conversations between China and Italy to showcase the cooperation achievements. (Graphic: Business Wire)
Guangzhou, a metropolis in southern China, has been a trade gateway of China to the world for more than two thousand years.
According to Sun Yong, publicity director of Nansha District of Guangzhou, “At that time, Guangzhou received merchant ships from all over the world including Italy, when marked the prosperity of Maritime Silk Road.”
“Today, the world's largest luxury ro-ro passenger ship MOBY, operating in the Italian Mediterranean, was actually built by Guangzhou Shipyard International based in Nansha,” Sun continued, “we are still connected.”
Michele De Gasperis, President of the Italian One Belt One Road Institute, said that Guangzhou is not only a beautiful city, but also a city full of business opportunities.
“Recently I visited the Canton Fair held in Guangzhou and was deeply impressed. I firmly believe that Guangzhou will become an important trade and tourism destination in Italy,” said Gasperis.
During the event, the Italian pianist Giuseppe Ganzerli, performed with PEARL River piano. “I started to import Pearl River piano from Guangzhou for more than ten years. Pearl River is a beautiful river across Guangzhou city. I always tell my Italian clients that this piano is so beautiful just like the Pearl River itself,” said Gennaro Schlitzer, board member of Queen’s SRL.
Several chefs from Guangzhou Restaurants Group demonstrated Guangzhou cuisine at the event.
“Canton is famous for its unique cuisine, which has reached every corner of the world. But our relationship goes far beyond cooking,” Angelo Tabaro, former minister for culture of the Veneto Region said.
“Italy and China are the two nations with the longest-lived and richest cultural heritages.” He added, “From painting to music, literature to architecture, both countries have influenced the world in unique ways. Italian and Chinese companies collaborate in sectors ranging from automobiles to fashion, from technology to renewable energy.”
Edouard Suzeau, a young designer from Guangzhou Automobile Group (GAC) Design Studio Milan, said that “Milan was chosen as the location for our studio because the city’s ubiquitous car culture is a perfect fit with GAC’s mission and passion for automotive design.”
A modern sculpture called Embrace the World made by Guangzhou artist Zeng Zhenwei, was given to Laura Gallon, President of the Italian Arte Laguna Prize. “I believe that the art and culture exchange between our two nations can be carried forward,” Gallon said.
Statistic shows that in 2022, the bilateral trade volume between China and Italy reached US$77.9 billion, hit a record high.
“More exchanges in all sectors are expected,” Li Ran from China southern airlines said, “For example, we currently operate four round-trip flights per week between Guangzhou and Rome, and will increase to six per week in December this year.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231118396482/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
